Abstract
Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Current Respiratory Medicine Reviews
Title: New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III
Volume: 3 Issue: 2
Author(s): Marcus B. Conde and Margarita Elsa Villarino
Affiliation:
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Abstract: Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Export Options
About this article
Cite this article as:
Conde B. Marcus and Elsa Villarino Margarita, New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III, Current Respiratory Medicine Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339807780599144
DOI https://dx.doi.org/10.2174/157339807780599144 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Antitrypanosomal and Antimycobacterial Activities of Coumarin N-acylhydrazonic Derivatives
Medicinal Chemistry Immune Restoration Disease: A Consequence of Dysregulated Immune Responses After HAART
Current HIV Research FDG-PET Imaging in Sarcoidosis
Current Medical Imaging Appropriate Use of Antibiotics for the Management of Respiratory Tract Infections
Infectious Disorders - Drug Targets Antimicrobial, Antitumor and Side Effects Assessment of a Newly Synthesized Tamoxifen Analog
Current Topics in Medicinal Chemistry Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Synthesis and Anti-cancer Activities of Apigenin Derivatives
Medicinal Chemistry Bixin Action in the Healing Process of Rats Mouth Wounds
Current Pharmaceutical Biotechnology An Overview of Neolignans of the Genus Piper L.: Isolation Methods and Biological Activities
Mini-Reviews in Medicinal Chemistry Modern Drug Discovery Technologies: Opportunities and Challenges in Lead Discovery
Combinatorial Chemistry & High Throughput Screening 3D-QSAR Approaches in Drug Design: Perspectives to Generate Reliable CoMFA Models
Current Computer-Aided Drug Design Universal Nature of Spondyloarthropathy as a Reactive Disease, Reflecting Differential Sensitivities
Current Rheumatology Reviews Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry Role of Lipopolysaccharides in Potential Applications of Nanocarrier Systems
Current Pharmaceutical Design Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Drug-Induced Hypokalaemia
Current Drug Safety Transcriptional Regulation and Expression of CYP3A4 in Hepatocytes
Current Drug Metabolism Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery